Metsera (MTSR) Jumps 20% as Big Pharma Battle Heats Up Over Takeover

Group 1 - Metsera Inc. (NASDAQ:MTSR) experienced a 20% increase in share prices week-on-week due to a bidding war between pharmaceutical giants for its acquisition [1] - Novo Nordisk submitted an $8.5 billion offer for Metsera, which is 16% higher than Pfizer's $7.3 billion offer, despite Pfizer having secured approval for the merger previously [2] - Pfizer is preparing to sue Metsera and Novo Nordisk, claiming that the new proposal violates their agreement and attempts to suppress competition [3][4] Group 2 - Pfizer had previously announced plans to acquire Metsera to strengthen its position in the weight-loss industry, focusing on obesity and cardiometabolic diseases [5] - The article suggests that while Metsera has potential as an investment, there are AI stocks that may offer higher returns with limited downside risk [6]